ArticleFrontiers in cellular and infection microbiology2026
Enhanced detection of low-level viremia by cobas 5800/6800 testing systems: a multi-center evaluation and clinical calibration study in China.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: With the advent of more sensitive HIV-1 viral load (VL) testing systems, a greater number of low VL samples can be identified. However, for some patients who were previously virally suppressed, the new testing system may yield discordant results, posing challenges for clinical decision-making. This study systematically evaluated and compared the performance of the cobas 5800/6800 testing systems and the cobas AmpliPrep/cobas TaqMan (CAP/CTM) testing systems. Methods: The performance of the cobas 5800/6800 and CAP/CTM systems was assessed in terms of quantitative accuracy, precision, limits of detection, linearity, and clinical performance. A multi-center evaluation involving 18 sub-centers was conducted, and correlation and agreement analyses were performed on the quantitative results between the systems. The VL distribution among 1,486 patients in Yunnan Province was also analyzed to evaluate the impact of switching to the cobas 6800 system. Results: All the systems achieved a quantitative bias within 0.25 log and intra-run CV% below 5% at 10,000 and 1,000 IU/mL, while CAP/CTM demonstrated a CV% slightly exceeding 5% at 100 IU/mL. The limits of detection (cobas 5800/6800: 24 IU/mL; CAP/CTM: 30 IU/mL) matched manufacturer specifications, with all systems showing excellent linearity (R²=0.9965-0.9990) and subtype coverage. Correlation analysis showed strong associations (R²>0.90), yet the quantitative results of cobas 5800 and cobas 6800 showed a modestly higher, but consistent bias compared to CAP/CTM. Analysis of the VL distribution showed that switching to the cobas 6800 testing system significantly increased the proportion of VL between 20-200 copies/mL; however, no significant difference was observed after calculation using the correlation coefficient obtained from the multi-center evaluation. Conclusion: In summary, both the legacy and new testing systems exhibited excellent performance in detecting HIV-1 subtypes prevalent in China. This study provides reliable data to enable more accurate assessment of viral suppression efficacy during the transition period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.